# IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07441174/  
OnCo record `nct07441174` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07441174 by InxMed (Shanghai) Co., Ltd., with 92 participants planned, started 2026-02-28 and due to reach its primary completion in 2031-02-28. Interventions recorded: IN10018 in combination with RNK08954.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07441174
- Phase: 1/2
- Setting: A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07441174: https://clinicaltrials.gov/study/NCT07441174

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [IN10018](https://onco.cc/drugs/in10018/)
- companies: [Ranok Therapeutics (Hangzhou)](https://onco.cc/companies/ranok-therapeutics-hangzhou/)

---
JSON: https://onco.cc/api/v1/entities/nct07441174.json